Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Inventory (2021 - 2025)

Apellis Pharmaceuticals (APLS) has 5 years of Change in Inventory data on record, last reported at $8.7 million in Q4 2025.

  • For Q4 2025, Change in Inventory rose 186.4% year-over-year to $8.7 million; the TTM value through Dec 2025 reached $15.3 million, up 41.95%, while the annual FY2025 figure was $15.3 million, 41.95% up from the prior year.
  • Change in Inventory reached $8.7 million in Q4 2025 per APLS's latest filing, up from -$5.4 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $47.8 million in Q4 2023 and bottomed at -$14.0 million in Q1 2025.
  • Average Change in Inventory over 5 years is $9.4 million, with a median of $12.9 million recorded in 2022.
  • Peak YoY movement for Change in Inventory: soared 10461.81% in 2024, then tumbled 193.81% in 2025.
  • A 5-year view of Change in Inventory shows it stood at $14.6 million in 2021, then surged by 77.33% to $26.0 million in 2022, then surged by 84.18% to $47.8 million in 2023, then plummeted by 120.96% to -$10.0 million in 2024, then soared by 186.4% to $8.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Inventory were $8.7 million in Q4 2025, -$5.4 million in Q3 2025, and $26.0 million in Q2 2025.